Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate

At the end of last week, Puma Biotechnology Inc (NYSE:PBYI) announced the filing of an NDA for its lead breast cancer candidate, as well as releasing some updated results relating to the long term efficacy and safety of the drug.

The company is up more than 20% heading into the US open on Monday, as speculation that the FDA will approve neratinib, the drug in question, at some point early to mid 2017. The gains underline the potential impact of an approval for Puma, so ahead of any action from the FDA, let’s take a look the science that underpins the drug and the data on which the application rests, in an attempt to estimate the chances of approval.

Neratinib is what’s called a tyrosine kinase inhibitor. We’ve discussed this type of drug in quite a lot of detail in the past here at Market Exclusive, but for those new to the science, here’s a quick overview of how it works.

test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease,

science photo/

Tyrosine kinase is a type of enzyme that plays a role in a process called signal transduction. Cells have receptors on the outside of them, and these receptors, when activated, transfer messages through the cell membrane to the DNA with the goal of eliciting some type of response. This response varies, depending on the cell and the receptors in question. The target responses in many of these development stage oncology treatments are replication, growth, proliferation, that sort of thing. For the messages to travel to the DNA, something needs to add a phosphate group to a protein, activating the latter. This something is tyrosine kinase. By inhibiting tyrosine kinase, neratinib stops the signal transduction process (as phosphorylation doesn’t happen) and the cell’s DNA doesn’t get the message to – in this case – replicate. This means the cancer cells don’t proliferate, and should (or so Puma hopes) stop breast cancer spreading.

That’s the science, what does the data show? The trial was called ExteNET, and it was a phase III safety efficacy effort, deigned to show superiority over placebo. In total 2,840 women were recruited, and dosed orally for one year with either neratinib or placebo. The data showed that the women dosed in the active arm of the trial (i.e. the ones who took neratinib) had a reduced risk of recurrence or death to the tune of 33% when compared to placebo. Safety was acceptable, with no real AEs outside of those expected on the back of this sort of treatment, and two-year disease free survival (DFS) in the neratinib group came in at 93.9% versus 91.6% for the placebo arm.

Basically, that’s great data. The application is for an adjuvant approval, so the drug will be administered after first line treatment, so any expansive effect that it has on first line (like the one the data showed neratinib has) is a real kicker for a drugs chances come PDUFA.

So what’s the potential impact of an approval? This is where we find out why Puma gained 20% on Friday – analysts put the peak sales estimate for the drug across the next decade at between $3 billion and $6 billion. This would make it one of the biggest selling drugs on the market. Puma’s got no drugs on the market as things stand, and has a market cap of a little over $1.3 billion. With a $6 billion candidate pending, there’s plenty of potential upside as the drug moves through the NDA process.

So what’s next? Well, now, it’s all about patience. There’s every chance the market will trade up slightly on Puma across the next couple of months, as we wait for the FDA acceptance of the application, but likely not to a huge degree. The big moves will come on acceptance (which just means the FDA is happy with the application’s completeness and sets a PDUFA) and, of course, beyond that, PDUFA. As mentioned above, if things run smoothly, we should be looking at a PDUFA some time before the end of H1 2017.

Follow Puma Biotechnology Inc. (NYSE:PBYI)
Trade (NYSE:PBYI) Now!

Note: This article is written by Mark Collins and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.